- Synergene received Certificate of Suitability (CEP) from EDQM for Fluconazole in the year 2022, Terbinafine Hydrochloride in the year 2022, Ambroxol Hydrochloride in the year 2024, Voriconazole in the year 2024 and Losartan Potassium in the year 2025
- Synergene received IDL from NMPA for Terbinafine Hydrochloride in the year 2024
- Synergene has filed USDMFs for Terbinafine Hydrochloride, Fluconazole, Losartan Potassium, Voriconazole, Irbesartan and the secondary USDMF for Escitalopram Oxalate
- Synergene has filed JDMFs for Escitalopram Oxalate, Terbinafine Hydrochloride and Luliconazole
- Synergene is currently filing USDMFs and CEPs for various APIs and Intermediates, and also DMFs in China, Japan, Brazil, Singapore to name a few.
- Synergene has so far filed DMFs in more than 50 countries for various APIs and Intermediates
